Institution
Memorial Sloan Kettering Cancer Center
Healthcare•New York, New York, United States•
About: Memorial Sloan Kettering Cancer Center is a healthcare organization based out in New York, New York, United States. It is known for research contribution in the topics: Cancer & Population. The organization has 30293 authors who have published 65381 publications receiving 4462534 citations. The organization is also known as: MSKCC & New York Cancer Hospital.
Topics: Cancer, Population, Breast cancer, Radiation therapy, Prostate cancer
Papers published on a yearly basis
Papers
More filters
TL;DR: A novel approach to modelling life expectancy, all-cause mortality and cause of death forecasts —and alternative future scenarios—for 250 causes of death from 2016 to 2040 in 195 countries and territories is provided.
1,118 citations
TL;DR: MAGIC as mentioned in this paper is a Markov affinity-based graph imputation of cells that shares information across similar cells, via data diffusion, to denoise the cell count matrix and fill in missing transcripts.
1,117 citations
University of Bonn1, Radboud University Nijmegen2, University of Chicago3, Université de Montréal4, University of Edinburgh5, Dresden University of Technology6, McGill University7, McGill University Health Centre8, Rockefeller University9, University of Cape Town10, Instituto de Medicina Molecular11, Eindhoven University of Technology12, Icahn School of Medicine at Mount Sinai13, University of Southern Denmark14, Cornell University15, Memorial Sloan Kettering Cancer Center16, Harvard University17, Broad Institute18, German Center for Neurodegenerative Diseases19, University of Massachusetts Medical School20
TL;DR: A group of leaders in the field define ‘trained immunity’ as a biological process and discuss the innate stimuli and the epigenetic and metabolic reprogramming events that shape the induction of trained immunity.
Abstract: Immune memory is a defining feature of the acquired immune system, but activation of the innate immune system can also result in enhanced responsiveness to subsequent triggers. This process has been termed 'trained immunity', a de facto innate immune memory. Research in the past decade has pointed to the broad benefits of trained immunity for host defence but has also suggested potentially detrimental outcomes in immune-mediated and chronic inflammatory diseases. Here we define 'trained immunity' as a biological process and discuss the innate stimuli and the epigenetic and metabolic reprogramming events that shape the induction of trained immunity.
1,116 citations
TL;DR: Patients with microscopically positive surgical margins or patients who present with locally recurrent disease are at increased risk for subsequent local recurrence and tumor-related mortality.
Abstract: PURPOSETo identify specific independent adverse clinicopathologic factors for event-free survival in a cohort of consecutively treated patients with extremity soft tissue sarcomas.PATIENTS AND METHODSProspectively collected data from a population of 1,041 adult patients with localized (American Joint Committee on Cancer [AJCC] stage IA to IIIB) extremity soft tissue sarcomas were analyzed. Patients were treated at a single institution between 1982 and 1994. Patient, tumor, and pathologic factors were analyzed by univariate and multivariate techniques to identify independent prognostic factors for the end points of local recurrence, distant recurrence, disease-specific survival, and post-metastasis survival.RESULTSThe 5-year survival rate for this cohort of patients was 76%, with a median follow-up time of 3.95 years. Significant independent adverse prognostic factors for local recurrence were age greater than 50 years, recurrent disease at presentation, microscopically positive surgical margins, and the h...
1,115 citations
Children's Hospital of Philadelphia1, Duke University2, Washington University in St. Louis3, Baylor University4, Brigham and Women's Hospital5, University of Pittsburgh6, University of Texas MD Anderson Cancer Center7, Vanderbilt University Medical Center8, Medical University of South Carolina9, Memorial Sloan Kettering Cancer Center10
TL;DR: A four-tiered system to categorize somatic sequence variations based on their clinical significances is proposed, with variants with strong clinical significance and variants with potential clinical significance in tier I; tier III, variants of unknown clinical significance; and tier IV, variants deemed benign or likely benign.
1,113 citations
Authors
Showing all 30708 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| Gordon H. Guyatt | 231 | 1620 | 228631 |
| Edward Giovannucci | 206 | 1671 | 179875 |
| Irving L. Weissman | 201 | 1141 | 172504 |
| Craig B. Thompson | 195 | 557 | 173172 |
| Joan Massagué | 189 | 408 | 149951 |
| Gad Getz | 189 | 520 | 247560 |
| Chris Sander | 178 | 713 | 233287 |
| Richard B. Lipton | 176 | 2110 | 140776 |
| Richard K. Wilson | 173 | 463 | 260000 |
| George P. Chrousos | 169 | 1612 | 120752 |
| Stephen J. Elledge | 162 | 406 | 112878 |
| Murray F. Brennan | 161 | 925 | 97087 |
| Lewis L. Lanier | 159 | 554 | 86677 |
| David W. Bates | 159 | 1239 | 116698 |
| Dan R. Littman | 157 | 426 | 107164 |